Titre:
  • Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
Auteur:Donskov, Frede; Motzer, Robert R.J.; Voog, Eric; Hovey, Elizabeth; Grüllich, Carsten; Nott, Louise L.M.; Cuff, Katharine; Gil, Thierry; Jensen, Niels Viggo; Chevreau, Christine; Negrier, Sylvie; Depenbusch, Reinhard; Bergmann, Lothar; Cornelio, Izzy; Champsaur, Anne; Escudier, Bernard; Pal, Sumanta; Powles, Thomas Bartholomew T.; Choueiri, Toni T.K.
Informations sur la publication:European journal of cancer, 126, page (1-10)
Statut de publication:Publié, 2020-02
Sujet CREF:Cancérologie
Mots-clés:Age
Cabozantinib
Everolimus
METEOR
Renal cell carcinoma
Tyrosine kinase inhibitor
Vascular endothelial growth factor receptor
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0959-8049
info:doi/10.1016/j.ejca.2019.10.032
info:pii/S0959804919308123
info:scp/85076919614